Cargando…

Cross-Regulation between Oncogenic BRAF(V600E) Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma

BACKGROUND: The BRAF(V600E) mutation leading to constitutive signaling of MEK-ERK pathways causes papillary thyroid cancer (PTC). Ras association domain family 1A (RASSF1A), which is an important regulator of MST1 tumor suppressor pathways, is inactivated by hypermethylation of its promoter region i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Seong Jin, Lee, Min Hee, Kim, Dong Wook, Lee, SeongEun, Huang, Songmei, Ryu, Min Jeong, Kim, Yong Kyung, Kim, Sung Jin, Kim, Soung Jung, Hwang, Jung Hwan, Oh, Sangphil, Cho, Heeyeong, Kim, Jin Man, Lim, Dae-Sik, Jo, Young Suk, Shong, Minho
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020965/ https://www.ncbi.nlm.nih.gov/pubmed/21249150 http://dx.doi.org/10.1371/journal.pone.0016180

Ejemplares similares

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAF(V600E)-Mutant Advanced Papillary Thyroid Carcinoma
por: Song, Eyun, et al.
Publicado: (2021)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Tumorigenesis of Papillary Thyroid Cancer Is Not BRAF-Dependent in Patients with Acromegaly
por: Kim, Hee Kyung, et al.
Publicado: (2014)

Induction of the BRAF(V600E) Mutation in Thyroid Cells Leads to Frequent Hypermethylation
por: Yi, Jin Wook, et al.
Publicado: (2022)

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation
por: Bae, Ja Seong, et al.
Publicado: (2016)

The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma
por: Kong, Joon Seog, et al.
Publicado: (2018)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma: Combined Analysis of Ultrasonography, Fine-Needle Aspiration Biopsy, and BRAF V600E Mutation
por: Kim, Seo Ki, et al.
Publicado: (2015)

Expression of NF2 Modulates the Progression of BRAF(V600E) Mutated Thyroid Cancer Cells
por: You, Mi-Hyeon, et al.
Publicado: (2019)

Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAF(V600E) mutations in papillary thyroid carcinoma
por: Yoon, Jung Hyun, et al.
Publicado: (2020)

Real-Time PCR Cycle Threshold Values for the BRAF(V600E) Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study
por: Park, Vivian Y., et al.
Publicado: (2015)

Mst1-FoxO Signaling Protects Naïve T Lymphocytes from Cellular Oxidative Stress in Mice
por: Choi, Juhyun, et al.
Publicado: (2009)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
por: Park, Charny, et al.
Publicado: (2015)

Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression
por: Kang, Yea Eun, et al.
Publicado: (2017)

The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades
por: Hong, A Ram, et al.
Publicado: (2014)

NAD(P)H: Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Polymorphisms in Papillary Thyroid Microcarcinoma: Correlation with Phenotype
por: Lee, Junguee, et al.
Publicado: (2013)

BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
por: Ahn, Hyo Yeong, et al.
Publicado: (2023)

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

Detection of BRAF(V600E) Mutations in Papillary Thyroid Carcinomas by Peptide Nucleic Acid Clamp Real-Time PCR: A Comparison with Direct Sequencing
por: Jeong, Dongjun, et al.
Publicado: (2012)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
por: Kang, So Young, et al.
Publicado: (2013)

BRAF(V600E) Mutation Enhances Estrogen-Induced Metastatic Potential of Thyroid Cancer by Regulating the Expression of Estrogen Receptors
por: Kim, Minjun, et al.
Publicado: (2022)

Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation
por: Byeon, Hyung Kwon, et al.
Publicado: (2016)

BRAF V600E and MAP2K1 Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma Cases
por: Shin, Sang-Yong, et al.
Publicado: (2015)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAF(V600E) Mutation-Negative Nodules?
por: Yoon, Jung Hyun, et al.
Publicado: (2015)

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
por: Paek, Se Hyun, et al.
Publicado: (2017)

Prognostic parameters for recurrence of papillary thyroid microcarcinoma
por: Kim, Tae Yong, et al.
Publicado: (2008)

MST4: A Potential Oncogene and Therapeutic Target in Breast Cancer
por: Arora, Ritu, et al.
Publicado: (2022)

Crif1 Deficiency Reduces Adipose OXPHOS Capacity and Triggers Inflammation and Insulin Resistance in Mice
por: Ryu, Min Jeong, et al.
Publicado: (2013)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
por: Simpson, Dennis A., et al.
Publicado: (2015)

Proper Indication of BRAF(V600E) Mutation Testing in Fine-Needle Aspirates of Thyroid Nodules
por: Koh, Jieun, et al.
Publicado: (2013)

Is Follow-up BRAF(V600E) Mutation Analysis Helpful in the Differential Diagnosis of Thyroid Nodules with Negative Results on Initial Analysis?
por: Yoon, Jung Hyun, et al.
Publicado: (2013)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence
por: Park, Seung-Jin, et al.
Publicado: (2022)

Artificial intelligence to predict the BRAF(V600E) mutation in patients with thyroid cancer
por: Yoon, Jiyoung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ib5bm3ak4a6sqsgqq5jrk4bor